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Abstract 
Aims  Intestinal absorption of esterified fatty acids depends on exocrine pancreatic function and influences plasma 
triglycerides levels. The aim was to investigate the association of reduced exocrine pancreatic function (low fecal 
elastase-1; FE1) with plasma triglycerides in type 2 diabetes and controls without diabetes. 
Methods FE1 (μg/g stool) and non-fasting plasma triglyceride measurements were undertaken in 544 type 2 
diabetes patients (age: 63 ± 8 years) randomly selected from diabetes registers in Cambridgeshire (UK), and 544 
matched controls (age, sex, practice) without diabetes. Linear regression models were fitted using FE1 as 
dependent and log-triglycerides as independent variable adjusting for sex, age, body mass index, alcohol 
consumption, serum lipase, HbA1c, and smoking. 
Results FE1 concentrations were lower (mean ± sd: 337 ± 204 vs. 437 ± 216 μg/g, p<0.05) and plasma triglycerides 
were higher (geometric mean */: standard deviation factor: 2.2*/:1.9 vs. 1.6*/:1.8 mmol/l, p<0.05) in type 2 
diabetes compared to controls, respectively. Within the category of type 2 diabetes and controls separately, a 10% 
increase in plasma triglycerides was associated with 4.5 μg/g higher FE1 concentrations (p<0.01) after adjusting 
for confounders. In contrast, in diabetes patients and controls with pathological FE1 (<100 μg/g), low FE1 levels 
were associated with high plasma triglycerides (significant only in controls). 
Conclusions Non-fasting triglycerides were positively related to FE1 in both type 2 diabetes and controls 
suggesting that impairment of exocrine pancreas function is influencing plasma triglycerides. Marked loss of 
exocrine pancreatic function had the opposite effect, resulting in higher levels of plasma triglycerides.   
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Introduction 
Morphological alterations of the exocrine pancreas are observed in patients with diabetes and a considerable 
number show mild to moderate impairment of bicarbonate and enzyme secretion (1). The pathophysiological 
mechanisms leading to impairment of exocrine pancreatic function in diabetes mellitus have not been elucidated, 
but may include imbalance of islet hormones, pancreatic fibrosis due to angiopathy, autoimmune mechanisms, 
autonomic neuropathy and altered release of gastrointestinal regulatory mediators (2).  
Pancreatic elastase 1 is an enzyme that is highly stable during passage through the gastrointestinal tract (3). The 
concentration of elastase 1 can be measured in faeces using an enzyme-linked immunosorbent assay (4). Faecal 
elastase-1 (FE1) levels have been demonstrated to correlate with more sensitive tests of pancreatic secretion, such 
as the secretin-caerulein test and resulting duodenal lipase activity (4). Low FE1 levels have also been shown to 
correlate with morphologic characteristics of chronic pancreatitis as detected with endoscopic retrograde 
pancreatography (5) and magnetic resonance cholangiopancreatography (6).  
In patients with type 2 diabetes, the prevalence of pancreatic exocrine insufficiency (PEI) estimated by low FE1 
measurements ranged between 12 and 73% in different studies (2). However, most of these studies only included 
small numbers of highly selected patients and have limited statistical power. In the largest population-based study 
so far, we randomly selected 544 type 2 diabetic patients (age: 63 years) from local diabetes registers in 
Cambridgeshire (UK), and 544 individually matched controls without diabetes (7). Low levels of FE1 (<100 µg/g) 
were found in 11.9% of cases and 3.7% of controls (age-sex-adjusted odds ratio (OR); 95% CI: 3.6; 2.2-6.2) (7). 
The most accepted definition of PEI is a reduction of exocrine pancreatic function to a level that results in 
malabsorption, demonstrated as a decreased coefficient of fat absorption (8,9).  However, exocrine dysfunction in 
patients with diabetes defined by low FE1 is usually mild to moderate and does not lead to steatorrhoea in the 
majority of cases. Thus, the clinical relevance of low fecal elastase in type 2 diabetes is questionable.  
Although decreased lipase activity in the intestine is a hallmark for PEI, little is known about the impact of PEI on 
plasma triglycerides in general. Intestinal absorption of esterified fatty acids depends on exocrine pancreatic 
function and influences plasma triglycerides levels. In a recent study, chronic pancreatitis patients with PEI 
according to the 13C mixed triglycerides breath-test were unexpectedly observed to have higher triglyceride 
concentrations than to those without PEI (10). Studies investigating the metabolic importance of mild and more 
severe impaired pancreatic exocrine function on triglyceride concentrations are lacking.  
To the best of our knowledge, the association of FE1 concentrations with plasma triglycerides in type 2 diabetes 
has not been investigated. Therefore, our study aimed (i) to investigate the association between FE1 concentrations 
and non-fasting plasma triglycerides in type 2 diabetes and in controls without diabetes adjusting for potential 
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confounders including age, sex, body mass index (BMI), HbA1c, smoking and alcohol intake and (ii) to evaluate 
the relationship of mild and more severe PEI (FE1 <100 μg/g) on plasma triglycerides. 
Methods 
Study population 
We analysed data from a case-control study in Cambridgeshire (UK) (7). Five-hundred-and-forty-four randomly 
selected type 2 diabetic patients from general practitioner registers in South Cambridgeshire (UK) were 
individually matched with 544 controls (diabetes excluded by HbA1c measurement, cut-off 7.0%). The matching 
variables were sex, age and practice. The presence of type 2 diabetes was primarily based on clinical criteria, e.g. 
onset of diabetes after the age of 30 years, and no insulin therapy during the first year after diagnosis. Because of 
the high prevalence of previously undiagnosed diabetes in patients of this age (mean age: 63 years), diabetes was 
not only excluded in controls by medical record search but also by normal glycated hemoglobin measurement 
using a cut-point of <7% which was accepted at the time of the study. 
The study was approved by the Cambridgeshire Local Research Ethics Committee. This analysis of the data was 
approved by the Ethical Committee of the Medical Faculty of the Heinrich Heine University Düsseldorf, Germany. 
All participants gave formal written consent after they had been instructed in detail about the study aims and 
investigations.  
Measurements 
FE1 measurements (µg/g stool) were performed centrally at ScheBo-Tech Institute in Wettenberg (Germany) blind 
to case-control assignation. Patients sampled a probe of their morning stool into a labeled stool tube that was 
collected by the investigators, frozen and dispatched to the laboratory on ice. Pathologically low levels of FE1 
were defined as <100 μg/g stool. 
Anthropometric measures were performed in light clothing using standardized methods. Detailed medical history 
was recorded by structured interviews and questionnaires. Current and historical alcohol consumption as well as 
smoking was assessed. Current alcohol intake was calculated as alcohol units per week. Among diabetic patients, 
diabetes duration and treatment was recorded. 
Whole blood was collected and delivered to the central laboratory at Addenbrooke’s Hospital, Cambridge, 
England, for measurement of HbA1c and plasma was collected for measurement of triglycerides using the RA 
1000 analyser (Bayer Diagnostics, Basingstoke, England). Other measurements were performed as previously 
described (7). 
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Statistical analyses 
Demographic variables of the study population were stratified by diabetes depending on their distributions by 
frequency tables, means ± standard deviations (SD), geometric means */: standard deviation factors (SDF) or non-
parametrically by medians (interquartile ranges). FE1 was analysed as a continuous variable assuming an 
approximate normal distribution, fitting the data better than a log-normal distribution. An approximate log-normal 
distribution was assumed for triglycerides. Scatter plots of FE1 versus log-triglycerides were carried out. Linear 
regression models were fitted using FE1 as dependent variable and log-triglycerides as independent variable. 
Potential confounders were sex, age (continuous), BMI (continuous), alcohol consumption (heavy drinking: 
ever/never), current heavy drinking (men: ≥21 g/day; women: ≥14 g/day), lipase (continuous), HbA1c 
(continuous), smoking and in the diabetes sub-population, insulin treatment (yes/no), and diabetes duration (< 5 
years, 5-10 years, > 10 years). In a first step, bivariate linear models were fitted using log-triglyceride and one 
confounder as independent variables in each model. Furthermore, a final model including all potential confounders 
was calculated using stepwise variable selection (log-triglycerides forced into the model). Analyses were also 
performed separately in the subgroup of subjects with pathological FE 1 (<100 µg/g). 
Finally, linear regression models with log-triglycerides as dependent and elastase as independent variable were 
fitted, separately for diabetes patients and non-diabetic controls. Sex, age, BMI, history of and current alcohol 
consumption, HbA1c, lipase, smoking, insulin therapy and diabetes duration were considered as potential 
confounders. Interaction variables between the subgroup indicator “elastase < 100 µg/g” and elastase were 
included in univariate and in final multivariate models. To evaluate multicollinearity in the regression models, 
Pearson and Spearman correlation matrices of all variables were calculated.  In addition, the variance inflation 
factor (VIF) was used to assess the extent to which the variances of the estimated coefficients were inflated. A 
variable with VIF >10 is considered as an indication of serious collinearity. Furthermore, a collinearity analysis 
estimating condition indices and proportions of variances was performed. Finally, reduced models excluding some 
of the covariates were fitted as a sensitivity analysis. Data from the collinearity analyses are not shown in detail. 
All analyses were carried out using SAS 9.4. 
Results  
The clinical characteristics of type 2 diabetes patients and controls are given in Table 1. After matching, the mean 
age was 63 years with a higher proportion of males (64%) in both groups. The mean diabetes duration was 7 years 
and two thirds of the patients were treated with oral antidiabetic drugs (insulin: 8.9%). The mean HbA1c was 7.9% 
in type 2 diabetes and 5.6% in controls (p<0.05). 
FE1 concentrations were significantly lower and plasma non-fasting triglycerides higher in patients with type 2 
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diabetes than in controls, respectively (both p<0.05) (Table 1). Whereas prevalence of patients with history of 
heavy alcohol consumption was higher in patients with type 2 diabetes, current alcohol intake was lower than in 
controls (p<0.05). There was no significant difference in smoking between the two groups. The prevalence of 
current gastrointestinal symptoms (diarrhea, constipation), the history of pancreatitis (ever) and serum lipase 
concentrations were also similar.  
A visual analysis of the scatterplot of FE1 and non-fasting triglycerides suggested a weak positive correlation in 
patients with type 2 diabetes (Figure 1). After fitting the regression line, higher triglyceride levels were associated 
with increased FE1 concentrations. As shown in Table 2, the positive relationship of triglycerides with FE1 
concentrations persisted after adjusting for potential confounders in the multivariate linear regression model (Table 
2). A 10% change in triglycerides was related to +4.5 µg/g (95%CI: 1.8-7.1 µg/g) FE1 concentrations. Age, male 
sex, and HbA1c (non-significant: p=0.060) were inversely related to the parameter of pancreatic exocrine function. 
Finally, BMI and serum lipase showed a positive relationship with FE1 (Table 2). There was no significant 
association with smoking. Triglyceride levels and the confounders explained about 10% of the variance in FE1. 
Examination of the scatterplot and regression line in controls without diabetes also showed a weak positive 
correlation between non-fasting triglycerides and FE1 (Figure 2). After adjusting for potential confounders in 
linear regression analysis, a 10% change in triglycerides was related to +4.5 µg/g (95%CI: 1.4-7.7 µg/g) FE1 in 
the control group, which was very similar to diabetes patients. Age, current heavy alcohol drinking and HbA1c 
showed an inverse association with FE1 in non-diabetic subjects, whereas a positive relationship was found with 
serum lipase concentrations (Table 3). The association with smoking was not significant. Triglyceride levels and 
confounders explained about 9% of the variance in FE1. Similar results were observed after excluding 13 patients 
with HbA1c values between 6.5-6.9% (data not shown). 
Visual inspection of the scatterplots indicated that the relationship between FE1 and triglycerides values was 
inverse in people with pathological FE1 (<100 µg/g) values. Therefore, an explorative regression analyses were 
carried out for the subgroup with pathological FE1 concentrations (<100 µg/g), consistent with a high probability 
of PEI. The prevalence of diarrhea or constipation was not significantly different comparing subjects with fecal 
elastase <100 and ≥100 µg/g in diabetes patients (diarrhea: 0.0 vs. 3.1%, p=0.24; constipation: 15.6 vs. 12.2%, 
p=0.42) or non-diabetic (diarrhea: 0.0 vs. 2.1%, p=1.00; constipation: 5.0 vs. 13.2%, p=0.495) patients. 
In contrast to the whole sample, in patients with type 2 diabetes with low FE1 levels (n=65) the plot indicates an 
inverse association of the pancreatic enzyme and triglycerides (Figure 3A). Similar result were also found in 
controls without diabetes (n=20) (Figure 3B). In both patients and controls regression parameters for log-
triglycerides (dependent variable FE1) in the univariate linear regression models were negative (ß-coefficient [95% 
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confidence limits] for diabetes: -7.98 [-18.50 to 2.55], p=0.135; patients without diabetes: -28.68 [-50.18 to -7.18], 
p=0.012). Multiple adjustment using the same confounders as in the whole sample (diabetes: sex, age, BMI, lipase, 
HbA1c, smoking; controls: age, alcohol, lipase, HbA1c, smoking) did not change these results.  
Finally, linear regression models with log-triglycerides as dependent and FE1 as independent variable were fitted 
(type 2 diabetes and controls). Overall, in type 2 diabetes patients there was a significant positive association 
between FE1 and (log-)triglycerides, which persisted after adjusting for the confounders (age, sex, BMI, HbA1c, 
diabetes duration, smoking). An increase of 100 µg/g FE1 was estimated to be related to an increase of 4.6% of 
triglycerides (95%CI: 2.0% to 7.3%). In the diabetes subgroup with FE1 concentrations <100 µg/g a non-
significant negative association between the marker of PEI and triglycerides was found, and the interaction 
between the subgroup and FE1 was also non-significant (p=0.092) in the confounder adjusted interaction model 
including the whole diabetic population. 
In controls, there was also a significant positive association between FE1 and (log-)triglycerides after adjusting 
for the confounders (age, sex, BMI, HbA1c, current alcohol consumption and smoking). An increase of 100 µg/g 
FE1 was associated with a 3% increase of triglycerides (95%CI: 0.8% to 5.3%). In contrast, in the subgroup (FE1 
<100 µg/g) a significant negative association was estimated, and the interaction between the subgroup and FE1 
was significant (p=0.036) in the confounder adjusted interaction model including the whole non diabetic 
population.  
There were some moderate significant correlations between the covariables of the model in both diabetes and non-
diabetic subjects (data not shown). Furthermore, some low to moderate collinearity was observed in both models, 
but sensitivity analyses showed that the main result of association between triglycerides and elastase was not 
affected (data not shown). 
Discussion 
The novel finding of the present study is that non-fasting plasma triglyceride concentrations are positively 
correlated with FE1 concentrations, a measure of pancreatic function, in patients with type 2 diabetes and in age-, 
sex- and practice-matched people without diabetes. Although lower FE1 values were found in type 2 diabetes 
patients than controls, the positive correlation between the marker of pancreatic function and non-fasting 
triglycerides was found in both groups. In contrast to this finding, a post-hoc analysis of subjects with pathological 
values of FE1 (<100 μg/g stool) demonstrated an inverse correlation between non-fasting plasma triglycerides and 
FE1. Thus, the study indicates that variation within the normal range of the exocrine pancreas function influence 
plasma triglyceride levels. In subjects with PEI, further loss of exocrine pancreatic function appears to have an 
opposite and pathophysiologically different effect, resulting in higher levels of plasma triglycerides.   
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Studies on the clinical consequences of moderately decreased FE1 concentrations are rare. Some studies have 
indicated that only a very pronounced reduction of FE1 is clinically relevant. One study in a cohort of patients 
with chronic pancreatitis found that steatorrhea was present only in cases with FE1 below 15 µg/g (11). Other 
studies have indicated that less pronounced reductions of FE1 might be relevant. For example, a high prevalence 
(59%) of pathological faecal fat excretion (>7g/day) was found in a study on patients with diabetes and FE1 <100 
µg/g stool (12). The mean FE1 concentration in this selected study sample was 56 µg/g (12). However, no 
significant correlation between FE1 and fat excretion was observed (12). 
There are several different mechanisms that may have contributed to the observed positive correlation between 
non-fasting triglyceride concentrations and FE1 concentrations in the total cohort. It could be speculated that an 
increased pancreatic lipase activity associated with higher FE1 levels (4), could contribute to a larger uptake of 
fatty acids and therefore increased production of chylomicrons in the intestine and very-low density lipoproteins 
in the liver (15,16). Also an association between impaired exocrine function and increased breakdown of very-low 
density lipoproteins (VLDL) is possible; if less chylomicrons are produced, enhanced hydrolysis of VLDL 
triglycerides is expected to occur in the post-prandial state contributing to reduced non-fasting triglyceride levels. 
Differences in dietary habits are another possible explanation as consumption of a high-fat diet is associated with 
high plasma triglycerides and may also increase pancreatic enzyme output. A study on the influence of diet 
composition on exocrine pancreatic output has demonstrated that ingestion of a high fat diet (40% of caloric 
content) resulted in a four times higher pancreatic enzyme output compared to a low fat diet (10% of total caloric 
content) (17). We did not have access to information on dietary habits in the current study and dietary fat intake 
may have confounded the observed association between FE1 and non-fasting triglycerides. New studies would be 
of value to understand how reduced exocrine function of the pancreas influences food intake and food preferences 
to fully understand the complex relationships between FE1 levels and plasma triglycerides. More research on 
gastrointestinal symptoms in type 2 diabetes patients related to low FE1 levels is also warranted. Additional factors 
that may have an impact on fecal elastase levels that we were not able to adjust for include undiagnosed celiac 
disease and some medications known to influence pancreatic secretion (i.e. cloroquine, octreotide). Increased 
plasma levels of triglycerides are associated with obesity, physical inactivity, smoking, excessive alcohol 
consumption, consuming a diet rich in carbohydrates and fat, some diseases (type 2 diabetes and insulin resistance, 
chronic renal failure, nephritic syndrome), use of certain medications (e.g. corticoid steroids, β-blockers, 
estrogens), genetic factors, low HDL, and high non-HDL cholesterol (13,14). We have been able to adjust for 
some but not all of these potential confounders in the present study, which needs to be further investigated. 
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The present study also identified factors other than triglycerides that are related to FE1 concentrations. In type 2 
diabetes and controls, higher age was inversely related to FE1. This finding confirms a previous cross-sectional 
study in subjects without gastrointestinal disease or diabetes (18). FE1 concentrations correlated negatively with 
age (Pearson r=-0.3531, P<0.001) and were significantly lower among people over 70 years old compared to 
younger controls (20-28 years old) (18). Thus, the mean age of study populations need to be taken into account 
when comparing results of various studies on FE1 concentrations. In type 2 diabetes, male sex was related to lower 
FE1 concentrations, which was also found in a previous study in type 1 diabetes (19).  Men with type 1 diabetes 
were about five times more likely to have FE1 values <100 µg/g compared to female patients (19). Furthermore, 
BMI was positively related to FE1 in type 2 diabetes. Also in patients with type 2 diabetes, PEI (defined by low 
FE1 and faecal chymotrypsin) was associated with lower BMI, without evidence of weight loss (20). In contrast 
with this finding, another cross-sectional study found predominance of FE1 levels <200 µg/g in obese diabetes 
patients (21). The authors raised the hypothesis that obesity and type 2 diabetes may have synergistic effects on 
the development of pancreatic exocrine insufficiency (21). Therefore, longitudinal studies are required to 
investigate the association of FE1 with body weight and weight change in patients with and without type 2 diabetes. 
Current heavy alcohol drinking was related to lower FE1 in people without diabetes. Interestingly, after excluding 
people with an alcohol consumption over 20 g per day, the prevalence of PEI based on low FE1 levels was 
considerably lower in a recent study compared to other investigations (22). Thus, the role of alcohol consumptions 
also needs to be considered when comparing studies on PEI in type 2 diabetes and controls. Serum lipase was 
positively related to FE1 levels both in diabetes and controls, indicating that the leakage of lipase is correlated to 
the function of exocrine pancreas. Finally, an inverse relationship was found between HbA1c and FE1 in both 
groups, which is in line with a previous study (23).   
In the sub-analysis of subjects with a pathological FE1 (<100 µg/g), there was an inverse association of 
triglycerides and FE1 concentrations that was statistically significant in controls with and without adjustment for 
potential confounders, but not significant in diabetes patients. Post-hoc analyses with log-triglycerides as 
dependent and FE1 as independent variable, separately for diabetes patients and non-diabetic controls, confirmed 
these relationships. There was a significant positive association between FE1 and triglycerides in type 2 diabetes 
patients and in the subgroup with low FE1 a negative association was found, although this was not statistically 
significant. Similar relationships were observed in controls. In the subgroup with FE1 <100 µg/g, a significant 
negative association was found in controls, and the interaction term indicated a significant effect modification of 
mild or severe PEI on the association between FE1 and triglycerides.  
10 
 
Hence, in the participants with a high probability of clinically significant PEI, a further decrease of residual 
pancreatic exocrine function is associated with increased plasma levels of triglycerides. Similar observations have 
been done in previous studies. In a recent study, blood nutritional markers were investigated in 114 people with 
chronic pancreatitis, 38 with and 76 without PEI, according to the 13C-mixed triglycerides breath tests (10). 
Chronic pancreatitis patients with PEI had higher average fasting triglyceride levels compared to those without 
PEI (mean (SD): 232 (445) mg/dl vs. 125 (88) mg/dl; p=0.05) (10). Another study comparing 20 patients with 
moderate to advanced chronic pancreatitis with 20 healthy controls reported differences in apolipoproteins and 
total cholesterol, and a non-significant trend towards higher plasma levels of triglycerides in patients with chronic 
pancreatitis (24).   
As a potential clinical consequence of our findings, a direct association between cardiovascular disease and chronic 
pancreatitis (severe exocrine pancreatic insufficiency) has been proposed (25) and more pronounced exocrine 
insufficiency leading to higher plasma triglycerides may be a contributing factor. This speaks in favor of early 
diagnosis and treatment of PEI in type 2 diabetes patients that already have an increased risk for cardiovascular 
events. Future research should also investigate the importance of enzyme supplementation in the regulation of 
plasma triglycerides in patients with very low FE1 and hypertriglyceridemia. 
It is reasonable to assume that the mechanisms behind the inverse association between FE1 and triglycerides in 
subjects with impaired exocrine pancreatic function are different from the mechanisms explaining the positive 
association between the same variables in subjects without evidence for PEI. It could be speculated that reduced 
intestinal fatty acid uptake and increased dietary intake of simple carbohydrates as a consequence of fat intolerance 
result in insulin resistance and increased de novo lipogenesis in the intestine and the liver, which in turn enhance 
triglyceride production in both tissues (15,16,26). The association between PEI and triglycerides may also be 
related to glucagon-like peptide 2 (GLP-2) (27,28). Interestingly, PEI increases the secretion of GLP-2, which is 
most likely due to delivery of a larger nutrient load to the distal part of the small intestine, where GLP-2 secreting 
L-cells are abundant (28). In healthy volunteers, an increase in postprandial triglycerides and free fatty acid 
concentrations was observed during GLP-2 administration (27). Moreover, experiments in mice and hamsters also 
showed that GLP-2 enhances absorption of fatty acids as well as increases production and secretion of 
chylomicrons (29,30). Thus, further studies are necessary to investigate the role of GLP-2 in PEI and lipid 
metabolism.  
There are a number of drawbacks of the present study that need to be mentioned. The use of a direct pancreatic 
function test like the secretin test would have given more reliable estimates of exocrine pancreatic function (31). 
However, direct pancreatic function tests are invasive and not suitable to use as screening tests. Fecal elastase was 
11 
 
selected as method for estimation of exocrine pancreatic function in this study based on the previously established 
correlation between fecal elastase and the secretin test (32, 33). In-depth analysis of clinically overt signs of PEI 
in patients with low fecal elastase levels was not possible in this study since limited information was available. 
Furthermore, beyond HbA1c, we had no other measures of glucose metabolism and insulin sensitivity in patients 
with type 2 diabetes and the control group. Next, plasma triglycerides were measured in a non-fasting state. 
However, it has been shown that at most plasma triglycerides changed minimally in response to normal food intake 
in individuals in the general population (34). New studies would be of value to understand how fasting and post-
prandial triglyceride levels are influenced by exocrine dysfunction of the pancreas. Furthermore, assessment of 
important confounders (e.g., alcohol intake) was undertaken using self-report questionnaires, which introduces the 
possibility of measurement error in these confounding factors and, therefore, residual confounding when they are 
adjusted for in the analysis. We also had no information on dietary habits that potentially can influence both FE1 
levels and plasma triglycerides. Finally, controls were not randomly selected from the practices but were 
individually matched to patients with type 2 diabetes. However, because we matched only by age, sex, and general 
practice and participants were randomly selected from the general practice register, the group of controls is broadly 
representative of people in Cambridgeshire of a similar age to the people with diabetes. The analyses for FE1 < 
100µg/g were planned post hoc and are based on small subsamples with low power. The results on the subgroups 
should therefore be interpreted in an explorative manner. The proportion of the variance in the FE1 values 
explained by all the independent variables in the regression equation together was only 9-10%, which is often 
found in epidemiological studies. The other covariables in the linear model were primarily considered as confoun-
ders, because it was not the goal to fit a model describing the full functionality of elastase depending on different 
risk factors. 
In conclusion, in this cross-sectional study we have observed that high FE1 levels are associated with high non-
fasting triglycerides in the total cohort of participants with and without diabetes. The opposite was observed in the 
subgroup of people with a suspicion of clinically relevant PEI as indicated by FE1 <100 µg/g, where low FE1 was 
associated with high non-fasting plasma triglycerides. Our findings suggest that exocrine pancreatic function 
measured as FE1 may have an impact on triglyceride turn-over and that this association is different in participants 
with and without PEI. However, the importance of exocrine pancreatic function for plasma triglyceride regulation 
needs to be confirmed in longitudinal investigations with more complete analysis of plasma lipid profile and full 
characterization of dietary habits. 
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Table 1 Characteristics of 544 patients with type 2 diabetes and 544 age-, sex-, and practice-matched non-diabetic 
controls (Cambridgeshire, UK) 
Variables Type 2 diabetes Controls 
  Age (years) 63 ± 8 63 ± 8 
  Males (%) 64 64 
  Body mass index (kg/m2) 29.7 ± 5.2*  27.4 ± 4.2  
  HbA1c (%) 7.9 ± 1.4*  5.6 ± 0.4  
  Diabetes duration (years)  7.3 ± 7.0  - 
  Oral antidiabetic agents (%) 65.6  - 
  Insulin treatment (%) 8.9  - 
  Faecal elastase 1 (µg/g stool) 337 ± 204* 437 ± 216 
  Triglycerides (non-fasting) mmol/l 2.2 [1.9]*  1.6 [1.8] 
  Alcohol intake:   
    Heavy drinking (ever, %) 16*  9  
    Alcohol units/week  1.5 (0.0-9.0)* 4.9 (0.8-12.4)  
  Smoking:   
    Current (%) 14 13 
    Ex-smoker (%) 60 58 
Current gastrointestinal symptoms (%):   
   Diarrhea 2.8 2.0 
   Constipation 12.6 12.9 
Pancreatitis (ever, %) 0.9 0.6 
  Lipase (U/L)      247 ± 79 247 ±  61  
N <10 missings in each variable, except for alcohol intake (24 missing)  
Data are mean ± SD, median (interquartile range), proportions or geometric mean */: [standard deviation factor] 
(triglycerides) 
* p<0.05 (diabetes vs controls): paired t-tests, McNemar or Bowkers tests 
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Figure 1 Scatterplot and regression line of faecal elastase 1 (µg/g stool) and non-fasting triglycerides (mmol/l) in 
type 2 diabetes patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
thick green line:  regression line  
 
 
thin green lines:  95% confidence limits for the expected value (mean) of the dependent variable  
thin red lines:  95% confidence limits for an individual prediction 
 
Data are presented as triglycerides on a log scale (area restricted to 0.3-10 mmol/l)  
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Figure 2 Scatterplot and regression line of faecal elastase 1 (µg/g stool) and non-fasting triglycerides (mmol/l) in 
non-diabetic controls 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
thick green line:  regression line  
 
 
 
thin green lines:  95% confidence limits for the expected value (mean) of the dependent variable  
thin red lines:  95% confidence limits for an individual prediction 
 
Data are presented as triglycerides on a log scale (area restricted to 0.3-10 mmol/l)  
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Figure 3A Scatterplot and regression line of faecal elastase 1 (µg/g stool) and non-fasting triglycerides (mmol/l) 
in type 2 diabetes patients with elastase 1 <100 µg/g (n=65) 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
thin green lines:  95% confidence limits for the expected value (mean) of the dependent variable  
thin red lines:  95% confidence limits for an individual prediction 
 
Data are presented as triglycerides on a log scale (area restricted to 0.3-10 mmol/l)  
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Figure 3B Scatterplot and regression line of faecal elastase 1 (µg/g stool) and non-fasting plasma triglycerides 
(mmol/l) in people without diabetes with elastase 1 <100 µg/g (n=20) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
thin green lines:  95% confidence limits for the expected value (mean) of the dependent variable  
thin red lines:  95% confidence limits for an individual prediction 
 
Data are presented as triglycerides on a log scale (area restricted to 0.3-10 mmol/l)  
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Table 2 Association of faecal elastase 1 concentrations (dependent variable) with non-fasting plasma triglycerides 
in type 2 diabetes: multivariate linear regression analyses (after stepwise selection) 
 
Variables 
 
ß-Coefficient 
 
95%CI (ß) 
 
p-value 
 
Intercept 
 
417.68 
 
195.98, 639.38 
 
- 
Triglycerides (mmol/l) (log) 46.88  18.78, 74.98 0.001 
Male sex -69.44 -106.60, -32.29 < 0.001 
Age (year) -2.85 -5.05,  -0.66 0.011 
Body mass index (kg/m2) 3.98 0.54, 7.42 0.023 
Lipase (U/l) 0.30 0.09, 0.51 0.005 
HbA1c (%) -11.72 -23.94, 0.50 0.060 
Current Smoker -37.90 -93.19, 17.39 0.179 
Ex-Smoker  18.87 -21.65, 59.39 0.361 
R2: 0.103 
n=535 (9 patients excluded because of missing values in the independent variables) 
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Table 3 Association of faecal elastase 1 concentrations (dependent variable) with non-fasting plasma triglycerides 
in non-diabetic controls: multivariate linear regression analyses (after stepwise selection) 
 
Variables 
 
ß-Coefficient 
 
95%CI (ß) 
 
p-value 
 
Intercept 
 
1153.17 
 
875.76, 1430.57 
 
- 
Triglycerides (mmol/l) (log) 47.72 14.88, 80.56 0.004 
Age (year) -3.78 -6.16, -1.40 0.002 
Heavy alcohol drinking (last month) -58.31 -112.48, -4.14 0.035 
Lipase (U/l) 0.30 0.001, 0.59 0.049 
HbA1c (%)  -97.20 -143.65, -50.75 <0.001 
Current Smoker -55.65 -116.23, 4.93 0.072 
Ex-Smoker  -23.17 -64.64, 18.30 0.273 
R2: 0.093 
n=520 (24 patients excluded because of missing values in the independent variables) 
 
